SCHEMBL8723636

SCHEMBL8723636

CCCCN(C(=O)c1cccs1)c1ccc2scc(C3CCC4CCCCN4CC3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
DRD2 P14416 1/20 0.35
SLC6A4 P31645 1/20 0.35
HRH3 Q9Y5N1 2/20 0.34
OPRM1 P35372 2/20 0.34
OPRK1 P41145 2/20 0.34
HPGD P15428 1/20 0.33
KDM4E B2RXH2 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CHRM2 P08172 2/20 0.32
CHRM3 P20309 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8721036 0.84 DRD2 (0.39) DRD2SLC6A4HRH3OPRM1OPRK1
SCHEMBL8723720 0.80 DRD2 (0.35) DRD2SLC6A4HRH3OPRM1OPRK1
SCHEMBL8721795 0.76 KMT2A (0.46) RAB9AALDH1A1MEN1LMNAKMT2A
SCHEMBL7481343 0.74 NOS3 (0.58) DRD2NOS3NOS1
SCHEMBL8722116 0.73 HRH3 (0.43) LMNADRD2SLC6A4HRH3OPRM1
SCHEMBL8720762 0.73 HRH3 (0.42) ALDH1A1MEN1LMNAKMT2AHRH3
SCHEMBL8721050 0.72 MEN1 (0.35) ALDH1A1MEN1LMNAKMT2ATDP1
SCHEMBL8725960 0.72 DRD2 (0.35) MEN1KMT2ADRD2SLC6A4HRH3
SCHEMBL8721858 0.70 MAPT (0.42) RAB9ADRD2HRH3KDM4ECHRM2
SCHEMBL8706248 0.70 HRH3 (0.41) DRD2SLC6A4HRH3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D RAB9A 2333/4885ALDH1A1 563/4885MEN1 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.